CA
CRVS icon

Clearstead Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Clearstead Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$732 Sell
50
-153
-75% -$2.44K ﹤0.01% 2080
2025
Q4 		$1.57K Buy
+203
New +$1.6K ﹤0.01% 2172

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Clearstead Advisors's CRVS Position: Q1 2026 in Review

Clearstead Advisors reduced its Corvus Pharmaceuticals (CRVS) stake by 75% in Q1 2026, selling an estimated $2.44K and leaving 50 shares worth $732. The position accounts for ﹤0.01% of the portfolio, ranked #2080.

Clearstead Advisors first reported a position in CRVS in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.57K in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Clearstead Advisors held 50 shares of Corvus Pharmaceuticals worth $732 as of Q1 2026.
  • Clearstead Advisors sold 153 Corvus Pharmaceuticals shares in Q1 2026, an estimated $2.44K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #2080 holding.
  • Clearstead Advisors first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Clearstead Advisors's Corvus Pharmaceuticals position peaked at $1.57K in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.